Abg Innovation Capital Partners Iii Gp LTD Castle Biosciences Inc Transaction History
Abg Innovation Capital Partners Iii Gp LTD
- $1.1 Million
- Q3 2024
A detailed history of Abg Innovation Capital Partners Iii Gp LTD transactions in Castle Biosciences Inc stock. As of the latest transaction made, Abg Innovation Capital Partners Iii Gp LTD holds 36,747 shares of CSTL stock, worth $1.11 Million. This represents 95.1% of its overall portfolio holdings.
Number of Shares
36,747
Previous 36,747
-0.0%
Holding current value
$1.11 Million
Previous $799,000
31.16%
% of portfolio
95.1%
Previous 95.46%
Shares
4 transactions
Others Institutions Holding CSTL
# of Institutions
201Shares Held
24.5MCall Options Held
303KPut Options Held
30.3K-
Black Rock Inc. New York, NY3.04MShares$92.1 Million0.0% of portfolio
-
Wasatch Advisors Inc Salt Lake City, UT1.83MShares$55.2 Million0.26% of portfolio
-
Vanguard Group Inc Valley Forge, PA1.75MShares$52.9 Million0.0% of portfolio
-
Bellevue Group Ag Kuesnacht, V81.26MShares$38.2 Million0.61% of portfolio
-
Portolan Capital Management, LLC Boston, MA1.26MShares$38 Million2.85% of portfolio
About CASTLE BIOSCIENCES INC
- Ticker CSTL
- Exchange NASDAQ
- Sector Healthcare
- Industry Diagnostics & Research
- Shares Outstandng 26,297,000
- Market Cap $795M
- Description
- Castle Biosciences, Inc., a commercial-stage diagnostics company, focuses to provide diagnostic and prognostic testing services for dermatological cancers. Its lead product is DecisionDx-Melanoma, a multi-gene expression profile (GEP) test to identify the risk of metastasis for patients diagnosed with invasive cutaneous melanoma. The company als...